However, the development of anti-HER2 targeted therapy such as trastuzumab, pertuzumab, lapatinib and trastuzumab emtansine has significantly improved the prognosis of patients with HER2-positive breast cancer [4,10,11,12,13]. The gene discussed is ERBB2; the disease is breast carcinoma.